Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Nephrology/Urology
Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
A Phase Ib of Mushroom Powder in Biochemically Recurrent Prostate Cancer
AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy
Androgen Deprivation and Localized Radiotherapy to Metastases in Patients with Oligometastatic Hormone - Sensitive Prostate Cancer
CALGB 90203: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
Determination of the Reliability of Expresssed Prostatic Secretion and Post Massage Urine Biomarkers in the Detection of Prostate Cancer in Men Undergoing Biopsy for Prostate Cancer
Long Term Follow Up after Prostate Cancer
Pre-Surgical EPS Biomarkers as Predictors of Recurrence
Prostate Cancer Database
RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation with Pelvis Lymph Node or Prostate Bed Only Radiotherapy (SPORT)in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Metastatic, Androgen-Independent study for patients with Prostate Cancer
Phase IV, Hormone Refractory Prostate Cancer Study
A multicenter clinical study of the Sonablate 500 for the treatment of locally recurrent prostate cancer with HIFU
Are you looking for a treatment for newly diagnosed Prostate Cancer?
Prostate Cancer - A Phase III, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in patients with carcinoma of the prostate with biochemical failure after localized therapy
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
Soy Protein/Isoflavones and Venlafaxine in Treating Hot Flashes in Patients Receiving Hormone Therapy for Prostate Cancer CCCWFU 97405
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
S0421, "Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo For Patients with Advanced Hormone Refractory Prostate Cancer"
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Have you been diagnosed with prostate cancer? Has the cancer spread to the bone? Is your PSA rising? If so you may qualify for a clinical research trial for the treatment of bone metastases in men with hormone-refractory prostate cancer.
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Cancer: Research Survey Study Needs Men Recently Diagnosed with Prostate Cancer.
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Do you have Prostate Cancer?
Prostate Cancer that requires Hormone therapy.
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)
Prostate Cancer with/without bone metastasis
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Clinical trial to test a study drug in heart failure and renal (kidney) insufficiency
Prostate Cancer - Adult Men
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
A Phase II Study of Weekly Taxol and Estramustine for Treatment of Prostate Cancer Micrometastases after Radical Prostatectomy or Salvage Radiation Therapy
Diagnosis of Prostate Cancer Using Multigene Expression Signatures
Docetaxel and Estramustine versus Mitoxantrone and Prednisone for Advanced Hormone Refractory Prostate Cancer, Phase III
Sponsor: CALGB
Efficacy of combined prophylactic and on demand Sildenafil usage in potent men undergoing brachytherapy and hormonal therapy for localized prostate cancer.
Neoadjuvant/Adjuvant Docetaxel and Estramustine in Combination with Brachytherapy and Three-Dimensional Conformal Radiotherapy
Phase I Trial of Adenovirus- Mediated IL-12 Gene Transduction in Patients with Radiorecurrent Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Randomized Prospective Study Comparing Prophylactic and On Demand Sildenafil Citrate Usage Administered During and After Radiotherapy in Combination with or without Hormone Therapy versus Radiotherapy Alone for the Preservation of Erectile Function in Potent Patients with Clinically Localized Prostate Cancer.
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind , Dose-Ranging Clinical Trial To Study The Efficacy And Safety of 5, 15 or 25mg/day CyPat (Cyproterone Acetate) for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients
A Phase 3, Randomized, Open-label Study Evaluating DN-101 in Combination with Docetaxel in Androgen Independent Prostate Cancer (AIPC) (ASCENT2)
A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy with Autologous Antigen-Loaded Dendritic Cells For Asymptomatic Metastatic Hormone Refractory Prostate Cancer.
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone Refractory Prostate Cancer
Concerned about bone loss associated with your prostate cancer therapy?
Prostate Cancer Bone Loss Study.
Prostate Cancer Prevention Clinical Trial
Prostate cancer trial
A multicenter clinical study of the Sonablate® 500 (SB-500) for the treatment of locally recurrent prostate cancer with HIFU
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
A research study for prostate cancer patients
Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Phase II Study Of Antineoplaston A10 And AS2-1 Private Capsules In Patients
With Incurable, Stage C Or D Adenocarcinoma Of The Prostate
Phase II Study Of Antineoplaston A10 And AS2-1 Private Capsules In Combination With Total Androgen Blockade In Patients With Adenocarcinoma Of The Prostate
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Prostate
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Prostate
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer
Prostate Cancer
